Loading patent…
AssigneesPeking University Third Hospital, Institute of High Energy Physics, Chinese Academy of Sciences, Institute of Chemistry, Chinese Academy of Sciences
InventorsYouyi ZHANG, Han XIAO, Jingyuan LI, Xiaohong FANG, Zhonghe XU, Zhizhen LU, Mingliang ZHANG
Estimating the term…
The present invention relates to a composition as a transforming growth factor (TGF)-β suppressor which comprises an effective amount of guanidine compound or a pharmaceutically acceptable salt. More particularly, the present invention relates to a composition comprising a guanidine compound or a pharmaceutically acceptable salt thereof as a TGF-β suppressor, wherein the composition is characterized by suppression or reduction of TGF-β activity which is a cause of disease. The present invention relates to a method of treating various TGF-β associated diseases, the method comprising administering to the subject a composition comprising a guanidine compound or a pharmaceutically acceptable salt thereof as a TGF-β suppressor which can prevent or treat TGF-β associated diseases by suppressing or reducing TGF-β activity.
A composition as a transforming growth factor (TGF)-βsuppressor, the composition comprises an effective amount of guanidine compound or a pharmaceutically acceptable salt thereof, wherein the guanidine compound is selected from the group consisting of metformin, phenylbiguanide, 1,3-Di(o-tolyl)guanidine, and buformin.
A method of treating TGF-β associated diseases, the method comprising administering to the subject guanidine compound or a pharmaceutically acceptable salt thereof, which interacts with TGF-β to block the binding to its receptor and thereafter suppress TGF-β activity to treat TGF-β associated diseases, wherein the guanidine compound is selected from the group consisting of metformin, phenylbiguanide, 1,3-Di(o-tolyl)guanidine, and buformin.
Dependencies are inferred from the claim text.